Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety?

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.2147/JPR.S47182</td>
</tr>
<tr>
<td>Citable link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717594">http://nrs.harvard.edu/urn-3:HUL.InstRepos:11717594</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>
Long-term opioid treatment of chronic nonmalignant pain: unproven efficacy and neglected safety?

Igor Kissin
Department of Anesthesiology, Perioperative, and Pain Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

Background: For the past 30 years, opioids have been used to treat chronic nonmalignant pain. This study tests the following hypotheses: (1) there is no strong evidence-based foundation for the conclusion that long-term opioid treatment of chronic nonmalignant pain is effective; and (2) the main problem associated with the safety of such treatment – assessment of the risk of addiction – has been neglected.

Methods: Scientometric analysis of the articles representing clinical research in this area was performed to assess (1) the quality of presented evidence (type of study); and (2) the duration of the treatment phase. The sufficiency of representation of addiction was assessed by counting the number of articles that represent (1) editorials; (2) articles in the top specialty journals; and (3) articles with titles clearly indicating that the addiction-related safety is involved (topic-in-title articles).

Results: Not a single randomized controlled trial with opioid treatment lasting $>3$ months was found. All studies with a duration of opioid treatment $\geq 6$ months ($n=16$) were conducted without a proper control group. Such studies cannot provide the consistent good-quality evidence necessary for a strong clinical recommendation. There were profound differences in the number of addiction articles related specifically to chronic nonmalignant pain patients and to opioid addiction in general. An inadequate number of chronic pain-related publications were observed with all three types of counted articles: editorials, articles in the top specialty journals, and topic-in-title articles.

Conclusion: There is no strong evidence-based foundation for the conclusion that long-term opioid treatment of chronic nonmalignant pain is effective. The above identified signs indicating neglect of addiction associated with the opioid treatment of chronic nonmalignant pain were present.

Keywords: addiction, chronic pain, neuropathic pain, opioids, overdose death, quality of evidence, treatment efficacy

Introduction
Only relatively recently in the history of medicine, was there a need to demonstrate quality of evidence and strength of recommendations to validate treatment effectiveness. Such support has been provided for various treatments of acute pain with opioids. Opiates have been used for treatment of acute and persistent pain for centuries, before the current standards of evidence quality became the norm. Compared to this, the treatment of chronic nonmalignant pain with opioids is a relatively new development. For the period 1983–2012, PubMed has more than 2,000 articles on the opioid treatment of chronic nonmalignant pain, but almost no articles on this topic.
before then. In regards to the Bonica pain clinic treatment practices from 1960–1980, Loeser wrote that

“it did not enter our minds that there could be a significant number of chronic pain patients who were successfully managed with opioids, because if there were any, we almost never saw them.”

This explains the almost complete absence of publications on the opioid treatment of chronic pain before 1983. The value of opioids in the treatment of chronic pain attributable to cancer was well recognized before the 1980s. As far as nonmalignant chronic pain is concerned, several initial publications were collected and summarized in the mid-1980s. The use of opioids for chronic pain management was introduced when the new standards of evidence-based medicine were already in the final stages of their establishment. Despite this, the opioid treatment of chronic pain came into practice without convincing proof of effectiveness. Since then, doubts about the effectiveness and safety of long-term treatment of chronic nonmalignant pain with opioids have been expressed in several reviews.

The goal of the present study was to test the following hypotheses: (1) there is no strong evidence-based foundation for the conclusion that long-term opioid treatment of chronic nonmalignant pain is effective; and (2) the risk of addiction – the main problem associated with the safety of such treatment – has been neglected. The available information pertinent to these hypotheses was analyzed using scientometric approaches.

**Methods**

The articles were collected mainly using the National Library of Medicine’s PubMed website (http://www.ncbi.nlm.nih.gov/PubMed). Articles published in English over the 30-year period of 1983–2012 were included. Keywords related to chronic pain (“chronic pain” OR “neuropathic pain”) were added to the terms related to opioids (“opioids” OR “narcotic analgesics” OR “morphine”). In addition, cancer pain and terminal illness were excluded from the search by placing in the search box the following: NOT (“cancer pain” OR “terminal illness”). Boolean operations were used, in which the following variables were selected: keywords, years of publications, and type of publications. In addition to the electronic search of articles, related publications were also searched manually in the reference lists of reports and reviews.

**Efficacy hypothesis**

Articles found in the searches were reviewed to make sure that they fit the definition of chronic pain. Articles with titles that lacked certain indication of pain duration, such as “persistent,” “persisting,” or “long-term” were checked and included in the database only if the duration of pain was ≥3 months. Criteria for excluding articles were: (1) inclusions of cases with malignant pain; (2) inclusions of treatments combining opioids with local anesthetics or antidepressants; (3) duration of treatment of 1 day (or <24 hours); and (4) having fewer than ten patients. To assess the quality of evidence for the efficacy for the treatment, the following factors were taken into consideration: the type of the study (randomized controlled trial [RCT] or not), the duration of opioid treatment (≥6 months or not), and the study conclusion on the treatment efficacy.

**Addiction hypothesis**

The following signs were used to determine whether attention to the addiction-related safety of long-term opioid treatment was insufficient: the number of journal editorials on this topic, the number of articles in the top specialty journals, and the number of journal articles with titles clearly stating that the addiction-related safety of the treatment is involved. The editorials (articles solicited by an editorial board to provide an editorial perspective on an article published in a journal) on several topics associated with the safety of long-term opioid treatment of chronic pain were selected in the following way: keywords related to chronic pain (“chronic pain” OR “neuropathic pain”) and opioids (“opioids” OR “narcotic analgesics” OR “morphine”) were combined with keywords associated with addiction (“addiction” OR “dependence” OR “abuse” OR “misuse”) or with overdose death (“death” OR “mortality” OR “fatality”). The article type was selected by using the PubMed filtering tool “Editorial.”

To quantitatively evaluate the presentation of the above topics in leading medical journals, the 20 top journals were selected with the approach used previously. The journal selection was based on two factors: (1) the rank of a journal sorted by the impact factor, as indicated by Journal Citation Report for 2011 (http://science.thomsonreuter.com) and (2) the journal specialty area. They included biomedical journals in general (ten journals), pharmacology (six journals), and psychiatry or neurology (four journals). The impact factor was used for the selection of journals in each specialty area category separately. The following journals were included: *Addiction, The American Journal of Psychiatry, Annals of Internal Medicine, Annals of Neurology, Archives of General Psychiatry, BMJ, The Journal of Clinical Investigation, The Journal of Pharmacology and Experimental Therapeutics, JAMA: The Journal of the American Medical Association, Lancet,*

To select articles with titles clearly indicating that they are devoted to specific topics (topic-in-title articles), the indicator “(Title)” was added to the selected terms placed into PubMed search boxes. All types of articles were used for this index also.

**Results**

**Efficacy hypothesis**

The electronic and manual search of the literature identified 2,356 articles. The results of this initial search were reviewed and reduced to 250 articles; see flowchart (Figure 1) and Supplementary material. Fifty-three articles were original clinical research articles on the opioid treatment of chronic nonmalignant pain (Table 1). Analysis of these publications revealed that 25 are reports of RCT studies, the rest are studies that lack a proper control group. Most of the RCT studies had a treatment duration of ≤1 month. Only one study is in the “≥3 months category” (90 days). The other randomized investigation with long treatment duration (16 weeks) was an open study. Table 2 presents 16 studies in which the duration of opioid treatment was ≥6 months, none of which is an RCT. Thus, there is not a single study that both fits the high quality of evidence category and has a long-term opioid treatment (duration of treatment ≥6 months). Systematic reviews on the opioid treatment of chronic nonmalignant pain have come to the same conclusion regarding long-term efficacy of the treatment, ie, there is insufficient evidence to make a definite conclusion (Table 3).

**Addiction hypothesis**

The results on the editorials related to addiction in chronic nonmalignant pain patients are presented in Table 4. There were no editorials on this topic in 1983–1992, one in

---

**Figure 1** Flow chart of screened, excluded, and included articles on chronic nonmalignant pain from 1983–2012.

**Abbreviation:** RCT, randomized controlled trial.
Table 1 Duration of opioid treatment in studies on chronic nonmalignant pain

<table>
<thead>
<tr>
<th>Duration of treatment</th>
<th>Number of studies without a proper control group</th>
<th>Number of randomized controlled trials</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>≤1 m</td>
<td>&gt;1 m–&lt;3 m</td>
</tr>
<tr>
<td>Years</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983–1992</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>1993–2002</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>2003–2012</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Total</td>
<td>9</td>
<td>1</td>
</tr>
</tbody>
</table>

Note: *Studies without a proper control group (see Grimes and Schulz)." Abbreviations: m, month; y, year.

Discussion
Efficacy hypothesis
Simple scientometric assessment of articles on long-term opioid treatment of chronic nonmalignant pain indicates the absence of high-quality evidence on efficacy. There is not a single RCT study lasting ≥3 months (Table 1). The longest randomized investigation (16 weeks) was limited by being an open study. All studies with opioid treatment ≥6 months (Table 2) were conducted without a proper control group; therefore, they do not provide the consistent good-quality evidence to support a strong clinical recommendation. Systematic reviews on opioid treatment of chronic nonmalignant pain have concluded that there is insufficient evidence to make a definite conclusion on the efficacy of long-term treatment.

Addiction hypothesis
The problem of safety of opioid treatment revealed itself most dramatically in rising numbers of opioid overdose deaths. According to the 2008 National Survey on Drug Use and Health (NSDUH) sponsored by the Substance Abuse and Mental Health Service Administration (SAMHSA), there has been at least a ten-fold increase in the medical use of opioids from 1988–2007. In 2007, 11,499 deaths were caused by overdoses of opioids, roughly a four-fold increase compared with 1999. Remarkably, even an increase of that size somehow did not trigger a timely response by the medical journals. This phenomenon is especially noticeable if one looks at the number of editorials on death associated with opioid treatment of chronic pain patients. Only two editorials on this topic were found (both late, in 2010–2011), as if there had been no dramatic increase in opioid-related deaths in 1999–2007. Opioid abuse, misuse, and addiction are the main reasons leading to the opioid overdose deaths. Somehow the...
<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Diagnosis</th>
<th>Opioid</th>
<th>Route of administration</th>
<th>Number of enrolled patients</th>
<th>Length of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>France et al</td>
<td>Case series (uncontrolled, retrospective, selected patients)</td>
<td>Back pain</td>
<td>Codeine, oxycodone, hydromorphone</td>
<td>Oral</td>
<td>16</td>
<td>6–22 months</td>
</tr>
<tr>
<td>Portenoy and Foley</td>
<td>Descriptive study (uncontrolled, retrospective, patients selected from two separate studies)</td>
<td>Back pain, postherpetic neuralgia, neuropathic pain</td>
<td>Oxycodone, methadone, levorphanol, codeine</td>
<td>Oral</td>
<td>38</td>
<td>6 months to 10 years</td>
</tr>
<tr>
<td>Zenz et al</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Back pain, neuropathic pain</td>
<td>Sustained-release dihydrocodeine, buprenorphine, sustained-release morphine</td>
<td>Oral</td>
<td>100</td>
<td>≥1 year (20 patients)</td>
</tr>
<tr>
<td>Kanoff</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Reflex sympathetic dystrophy, arachnoiditis</td>
<td>Morphine via implanted delivery system</td>
<td>Intrathecal</td>
<td>15</td>
<td>2–44 months</td>
</tr>
<tr>
<td>Hassenbusch et al</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Neuropathic pain</td>
<td>Morphine, sufentanil via implanted delivery system</td>
<td>Intrathecal</td>
<td>22</td>
<td>12–56 months (18 patients)</td>
</tr>
<tr>
<td>Tutak and Doleys</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Back pain</td>
<td>Morphine via implanted delivery system</td>
<td>Intrathecal</td>
<td>26</td>
<td>16–27 months</td>
</tr>
<tr>
<td>Angel et al</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Back pain, neuropathic pain</td>
<td>Morphine via implanted delivery system</td>
<td>Intrathecal</td>
<td>15</td>
<td>3 years (11 patients)</td>
</tr>
<tr>
<td>Anderson and Burchiel</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Neuropathic pain, nociceptive pain</td>
<td>Morphine via implanted delivery system</td>
<td>Intrathecal</td>
<td>40</td>
<td>24 months (20 patients)</td>
</tr>
<tr>
<td>Harati et al</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Diabetic neuropathy</td>
<td>Tramadol</td>
<td>Oral</td>
<td>117</td>
<td>6 months (100 patients)</td>
</tr>
<tr>
<td>Milligan et al</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Neuropathic pain, nociceptive pain</td>
<td>Fentanyl</td>
<td>Transdermal</td>
<td>532</td>
<td>12 months (301 patients)</td>
</tr>
<tr>
<td>Mironer and Tollison</td>
<td>Descriptive study (uncontrolled, prospective)</td>
<td>Back pain, neuropathic pain</td>
<td>Methadone</td>
<td>Intrathecal</td>
<td>24</td>
<td>6 months (9 patients)</td>
</tr>
<tr>
<td>Anderson et al</td>
<td>Uncontrolled study (prospective, randomized to morphine intrathecal infusion or its epidural injection)</td>
<td>Chronic nonmalignant pain</td>
<td>Morphine via implanted delivery system</td>
<td>Intrathecal</td>
<td>40</td>
<td>6 months (27 patients)</td>
</tr>
<tr>
<td>Allan et al</td>
<td>Uncontrolled study (prospective, multicenter, randomized to oral morphine)</td>
<td>Back pain</td>
<td>Fentanyl</td>
<td>Transdermal</td>
<td>680</td>
<td>13 months</td>
</tr>
<tr>
<td>Chao</td>
<td>Descriptive study (uncontrolled, retrospective)</td>
<td>Back pain, neuropathic pain</td>
<td>Sustained-release morphine</td>
<td>Oral</td>
<td>68</td>
<td>12 months</td>
</tr>
<tr>
<td>McLwain and Adheieh</td>
<td>Descriptive study (uncontrolled, prospective, multicenter)</td>
<td>Osteoarthritis</td>
<td>Extended-release oxymorphone</td>
<td>Oral</td>
<td>153</td>
<td>12 months (61 patients)</td>
</tr>
<tr>
<td>Portenoy et al</td>
<td>Uncontrolled registry study</td>
<td>Osteoarthritis, diabetic neuropathy, back pain</td>
<td>Controlled-release oxycodone</td>
<td>Oral</td>
<td>219</td>
<td>1–3 years (14–39 patients)</td>
</tr>
</tbody>
</table>
Table 3 Systematic reviews on opioid treatment of chronic pain

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of pain</th>
<th>Opioid</th>
<th>Route of administration</th>
<th>Duration of treatment</th>
<th>Conclusion on the treatment efficacy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kalso et al.</td>
<td>Osteoarthritis, diabetic neuropathy, peripheral neuropathic pain, phantom limb pain, postherpetic neuralgia, musculoskeletal pain</td>
<td>Morphine, oxycodone</td>
<td>Oral, transdermal, or intravenous</td>
<td>From 4 days to 8 weeks</td>
<td>The short-term efficacy of opioids was good in both neuropathic and musculoskeletal pain conditions. However, only a minority of patients went on to long-term management with opioids; therefore, a definite conclusion on long-term efficacy was unclear. Weak evidence suggests that oral and intrathecal opioids reduce pain long-term in the relatively small proportion of individuals who continue treatment. The small to moderate beneficial effects of opioids are outweighed by large increases in the risk of adverse events. Therefore, opioids should not be routinely used, even if osteoarthritic pain is severe.</td>
</tr>
<tr>
<td>Martell et al.</td>
<td>Back pain</td>
<td>Morphine, oxycodone, sustained-release morphine, controlled-release oxycodone, other opioids</td>
<td>Oral or transdermal, or intrathecal</td>
<td>From 7 days to 16 weeks</td>
<td>Opioids may be efficacious for short-term pain relief. Long-term efficacy was unclear.</td>
</tr>
<tr>
<td>Noble et al.</td>
<td>Neuropathic pain, osteoarthritis, back pain</td>
<td>Morphine, tramadol, methadone, controlled-release oxycodone, fentanyl, sufentanil, dihydrocodeine, buprenorphine</td>
<td>Oral, transdermal, or intrathecal</td>
<td>From 6–48 months</td>
<td>Weak evidence suggests that oral and intrathecal opioids reduce pain long-term in the relatively small proportion of individuals who continue treatment.</td>
</tr>
<tr>
<td>Nuesch et al.</td>
<td>Osteoarthritis</td>
<td>Codeine, morphine, oxycodone, oxymorphone</td>
<td>Oral or transdermal</td>
<td>From 3 days to 3 months</td>
<td>The small to moderate beneficial effects of opioids are outweighed by large increases in the risk of adverse events. Therefore, opioids should not be routinely used, even if osteoarthritic pain is severe.</td>
</tr>
</tbody>
</table>

Table 4 Editorials on opioid addiction in chronic pain patients

<table>
<thead>
<tr>
<th>Years</th>
<th>Number of editorials</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Addiction” AND “chronic pain”</td>
<td>“Addiction”</td>
</tr>
<tr>
<td>1973–1982</td>
<td>–</td>
</tr>
<tr>
<td>1983–1992</td>
<td>0</td>
</tr>
<tr>
<td>1993–2002</td>
<td>1*</td>
</tr>
<tr>
<td>2003–2012</td>
<td>4*</td>
</tr>
</tbody>
</table>

Notes: OR “dependence” OR “abuse” OR “misuse”: “OR “neuropathic pain” NOT (“cancer pain” OR “terminal illness”); reference 66; references 67–70.

Representation for all types of articles (including letters and commentaries) on opioid addiction in the top 20 journals was also insufficient: zero articles in 1993–2002 (10–15 years after the introduction of treatment) and five in 2003–2012 (Table 5).

The topic-in-title articles clearly announce the topic under discussion; however, if the topic is an undesirable problem, authors often try to avoid naming it explicitly in the title. The lack of topic-in-title publications indicates that the topic is a neglected one. As indicated in the results of the present study, death associated with opioid addiction in chronic pain patients was not reflected in titles from 1983–2002; in 2003–2012, it was found in the titles of only four articles (Table 7). This tendency also applied to addiction, abuse, misuse, or dependence in opioid treatment of chronic pain. In 1983–1992, there were only two topic-in-title articles related introduction of opioid treatment of chronic nonmalignant pain did not result in editorials on opioid addiction in chronic pain patients: there were five editorials related to this topic, four of them published only in 2003–2012. Compare this with 171 editorials on opioid addiction in general published during this period (Table 4).

Table 5 Articles on opioid addiction in chronic pain patients in the top 20 journals

<table>
<thead>
<tr>
<th>Years</th>
<th>Number of articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>“Addiction” AND “chronic pain”</td>
<td>“Addiction”</td>
</tr>
<tr>
<td>1973–1982</td>
<td>–</td>
</tr>
<tr>
<td>1993–2002</td>
<td>0</td>
</tr>
<tr>
<td>2003–2012</td>
<td>5*</td>
</tr>
</tbody>
</table>

to opioid addiction in chronic pain patients, at a time when there were 536 topic-in-title articles on opioid addiction in general (right side of Table 6). There were also profound differences in the numbers of addiction articles related specifically to chronic pain patients and to opioid addiction in general for the periods 1993–2002 and 2003–2012. Especially interesting was the decrease in the number of topic-in-title articles on opioid addiction in general during 1983–2002 (right side of Table 6) when opioid treatment for chronic nonmalignant pain was being introduced. Could the acceptance of this new indication for opioid treatment be responsible for such a change?

Estimates of the rate of addiction problems among chronic pain patients extremely varied. Hojsted and Sjogren reported that the rates of addiction associated with long-term opioid treatment were 0%–50% in noncancer patients and 0%–7.7% in cancer patients, depending on the subpopulation studied and the criteria used.108 This uncertainty is similar to that with the rate of iatrogenic addiction in patients treated with opioids for acute or subacute pain. A systematic review on this topic concluded, “It is not known whether the risk for iatrogenic addiction among patients treated with opioids for acute or subacute pain is relatively high (>10%) or low (0.1%).”151 The difficulty of estimating the risk of opioid addiction and abuse (see Jamison et al)152 calls into question the accuracy of reported rates of risk for opioid addiction.

One author of a study on the use of opioids in chronic nonmalignant pain has asked: “Is this treatment a lifetime sentence?”153 If not, another question should be: “Has the withdrawal syndrome after long-term opioid use been adequately studied?”; and not only acute withdrawal syndrome, but protracted withdrawal as well? The latter (also called protracted abstinence or chronic withdrawal syndrome) is characterized by generalized symptoms (e.g., discomfort, fatigue, decreased blood pressure, pulse rate, and body temperature) lasting 3–9 months.154-156 Long-lasting (3–4 months) neurobiological alterations following withdrawal from opioids have been well confirmed in animal experiments.157 Lack of knowledge regarding the risk of addiction and even greater uncertainty regarding protracted withdrawal following cessation of long-term opioid treatment of chronic pain call for studies with high-quality evidence that supports reliable recommendations.

This study has a limitation related to the absence of exact definition of chronic nonmalignant pain. It is associated with the lack of definition for chronic pain in general. For example, the International Association for the Study of Pain Task Force on Taxonomy – in the classification of chronic pain – has chosen not to define chronic pain.158

### Table 7

<table>
<thead>
<tr>
<th>Years</th>
<th>Number of articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>1973–1982</td>
<td>4</td>
</tr>
<tr>
<td>1983–1992</td>
<td>0</td>
</tr>
<tr>
<td>1993–2002</td>
<td>2</td>
</tr>
<tr>
<td>2003–2012</td>
<td>4</td>
</tr>
</tbody>
</table>

Notes: Articles with titles clearly indicating that they are devoted to death associated with opioid addiction in chronic pain patients; OR “mortality” OR “fatality;” OR “dependence” OR “abuse” OR “misuse;” OR “neuropathic pain” NOT (“cancer pain” OR “terminal illness”); references 145–148.

### Table 7

<table>
<thead>
<tr>
<th>Years</th>
<th>Number of articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>1983–1992</td>
<td>0</td>
</tr>
<tr>
<td>1993–2002</td>
<td>0</td>
</tr>
<tr>
<td>2003–2012</td>
<td>4</td>
</tr>
</tbody>
</table>

Notes: Articles with titles clearly indicating that they are devoted to death associated with addiction in chronic pain patients; OR “mortality” OR “fatality;” OR “dependence” OR “abuse” OR “misuse;” OR “neuropathic pain” NOT (“cancer pain” OR “terminal illness”); references 79–80; 81–93; 94–144.

### Conclusion

There is no high-quality evidence on the efficacy of long-term opioid treatment of chronic nonmalignant pain. As a result, the strength of any recommendation regarding this treatment is weak. The safety of opioid treatment in terms of risk of addiction and overdose death has not properly been assessed due to the complexity of these outcomes. Until 2003, opioid addiction associated with the treatment of chronic nonmalignant pain was clearly a neglected topic of publication. However, this topic is now beginning to receive the attention it deserves.

### Disclosure

The author reports no conflicts of interest in this work.

### References


Opioid treatment of chronic nonmalignant pain


Supplementary material


